Literature DB >> 33105685

Viewpoint: Origin of SARS-CoV-2.

Kenneth Lundstrom1, Murat Seyran2,3, Damiano Pizzol4, Parise Adadi5, Tarek Mohamed Abd El-Aziz6,7, Sk Sarif Hassan8, Antonio Soares6, Ramesh Kandimalla9,10, Murtaza M Tambuwala11, Alaa A A Aljabali12, Gajendra Kumar Azad13, Pabitra Pal Choudhury14, Vladimir N Uversky15, Samendra P Sherchan16, Bruce D Uhal17, Nima Rezaei18,19, Adam M Brufsky20.   

Abstract

The origin of the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) virus causing the COVID-19 pandemic has not yet been fully determined. Despite the consensus about the SARS-CoV-2 origin from bat CoV RaTG13, discrepancy to host tropism to other human Coronaviruses exist. SARS-CoV-2 also possesses some differences in its S protein receptor-binding domain, glycan-binding N-terminal domain and the surface of the sialic acid-binding domain. Despite similarities based on cryo-EM and biochemical studies, the SARS-CoV-2 shows higher stability and binding affinity to the ACE2 receptor. The SARS-CoV-2 does not appear to present a mutational "hot spot" as only the D614G mutation has been identified from clinical isolates. As laboratory manipulation is highly unlikely for the origin of SARS-CoV-2, the current possibilities comprise either natural selection in animal host before zoonotic transfer or natural selection in humans following zoonotic transfer. In the former case, despite SARS-CoV-2 and bat RaTG13 showing 96% identity some pangolin Coronaviruses exhibit very high similarity to particularly the receptor-binding domain of SARS-CoV-2. In the latter case, it can be hypothesized that the SARS-CoV-2 genome has adapted during human-to-human transmission and based on available data, the isolated SARS-CoV-2 genomes derive from a common origin. Before the origin of SARS-CoV-2 can be confirmed additional research is required.

Entities:  

Keywords:  COVID-19 pandemic; coronavirus; genome homology; natural selection; origin of SARS-CoV-2; receptor binding domain; zoonotic transfer

Mesh:

Substances:

Year:  2020        PMID: 33105685      PMCID: PMC7690418          DOI: 10.3390/v12111203

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


The COVID-19 pandemic has seriously touched the whole world with over 40 million infections and claiming more than 1 million lives as of today (21 October 2020), also causing social and economic havoc globally. There is currently a tremendous amount of both competitive and collaborative efforts in search of novel antiviral drugs and vaccines reaching almost desperate proportions. Among all this, the question of the origin of the “culprit”, the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), is being addressed. Numerous politically motivated conspiracy theories have surfaced, and hypotheses have arisen, including the unintentional or intentional escape/release of the virus from a high-security laboratory facility in Wuhan, China. For instance, it was reported [1] (now withdrawn) that SARS-CoV-2 contained four inserts in its spike (S) glycoprotein, critical for virus entry, which were either identical or similar to motifs found in the Env and Gag proteins of HIV-1. It was speculated that fragments from the HIV-1 genome had been intentionally introduced into the SARS-CoV-2 genome. A thorough bioinformatics analysis and sequence examination of SARS-CoV-2, other Coronaviruses, and HIV-1 from the GenBank database demonstrate that there is currently no compelling evidence that HIV-1 specific inserts in SARS-CoV-2 exist [2]. Additional analysis initially suggests that the probability is low that SARS-CoV-2 is a laboratory construct or intentionally engineered [3]. The self-assembled COVID consortium, consisting of international experts in bioinformatics, structural biology, molecular biology, immunology, and virology, has just published a Letter in the Journal of Medical Virology [4] in response to publications on the natural origin of SARS-CoV-2. It stated that despite the consensus of SARS-CoV-2 originating from bat CoV RaTG13, SARS-CoV-2 had demonstrated significant discrepancies to other human Coronaviruses related to host tropism. Moreover, bat and rodent Coronaviruses have seen some specific changes in the S protein receptor-binding domain (RBD) and the glycan-binding N-terminal domain (NTD) in host tropism [5,6]. However, SARS-CoV-2 sequences do not contain these changes, indicating a very recent origin of RBD and NTD subdomains. For instance, the hidden glycan-binding domains located in cavities in the S protein NTD domain, limiting their access to antibodies and immune cells, are not present in SARS-CoV-2 [6]. The surface of the sialic acid-binding domain of the SARS-CoV-2 S protein is flat and non-sunken, unlike other Coronaviruses, influenza viruses, rhinoviruses, and Meningo viruses showing “canyons”, depression zones, or cavities in accordance with the “Canyon hypothesis” [7]. Although previous cryo-EM structural and biochemical studies on furin-cleaved and native SARS-CoV-2 S protein and bat CoV RaGT13 S protein have indicated strong similarity, the native human S protein showed higher stability and a 1000-fold higher binding affinity to the human ACE2 receptor. It suggests that furin cleavage decreased the overall S protein stability and facilitated the open conformation required for viral particle binding to the ACE2 receptor [8]. Furthermore, it has been demonstrated that the D614G mutation in the SARS-CoV-2 S protein reduced S1 shedding and increased infectivity [9]. In contrast to bat RaTG13, SARS-CoV-2 recombination presumably occurs between the S1 and S2 domains in the S protein enabling the utilization of furin protease. Despite the analysis of numerous clinical isolates of the SARS-CoV-2 S protein, no alternative recombination seems to occur, suggesting that the furin S1/S2 cleavage site is unique for recombination. Moreover, the four amino acid insertion, which creates a novel furin cleavage site, supports it. Although human Coronaviruses frequently contain “hot spots” for non-synonymous amino acid replacements affecting host tropism/adaptation, resistance to neutralizing antibodies and immune evasion [10], only a single high-frequency non-synonymous mutation (D614G) has been identified from clinical SARS-CoV-2 isolates [11]. Based on these findings, the SARS-CoV-2 S protein does not occur as a mutational “hot spot” in contrast to other human Coronaviruses. So, the million-dollar question today is the origin of SARS-CoV-2. Why is this important? Perhaps a citation of Theodore Roosevelt is in place: “The more you know about the past the better you are prepared for the future”. Indeed, not only of scientific curiosity or finding someone to blame, but of practical awareness and preparation for potential emerging new outbreaks, the origin of SARS-CoV-2 is of utmost importance. As the current consensus within the scientific community strongly indicates, it is improbable (though not zero) that the SARS-CoV-2 emerged through laboratory manipulations. Two alternative hypotheses for the origin of SARS-CoV-2 have been presented [3]: natural selection in an animal host before zoonotic transfer or natural selection in humans following zoonotic transfer. In the earlier case, despite the high similarity between SARS-CoV-2 and bat Coronaviruses, such as bat Coronavirus RaTG13 (96% identical), there are significant discrepancies as we have pointed out. Moreover, some pangolin Coronaviruses exhibit high similarity to the RBD region in the SARS-CoV-2 S protein, including six RBD key residues [3,12]. In this latter case, the SARS-CoV-2 genome has been postulated to have adapted during undetected human-to-human transmission, which allowed the pandemic to accelerate [13]. It seems that sequence data accumulated from SARS-CoV-2 genomes so far indicate that the isolated SARS-CoV-2 genomes derived from a common ancestor. Moreover, the identification of a very similar RBD sequence in the pangolin Coronavirus S protein to the one found in SARS-CoV-2 S supports the susceptibility of transmission to humans. In any case, additional research is required before we can confirm the origin of SARS-CoV-2. In addition to our analysis on the SARS-CoV-2 S protein, we have also targeted the SARS-CoV-2 ORF8 and ORF10 proteins in comparison to other coronaviruses to further shed some light on the origin of SARS-CoV-2, which will soon be shared with the scientific community.
  11 in total

Review 1.  The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance.

Authors:  M G Rossmann
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

Review 2.  Receptor recognition mechanisms of coronaviruses: a decade of structural studies.

Authors:  Fang Li
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

Review 3.  Coronavirus Spike Protein and Tropism Changes.

Authors:  R J G Hulswit; C A M de Haan; B-J Bosch
Journal:  Adv Virus Res       Date:  2016-09-13       Impact factor: 9.937

4.  HIV-1 did not contribute to the 2019-nCoV genome.

Authors:  Chuan Xiao; Xiaojun Li; Shuying Liu; Yongming Sang; Shou-Jiang Gao; Feng Gao
Journal:  Emerg Microbes Infect       Date:  2020-02-14       Impact factor: 7.163

5.  A new coronavirus associated with human respiratory disease in China.

Authors:  Fan Wu; Su Zhao; Bin Yu; Yan-Mei Chen; Wen Wang; Zhi-Gang Song; Yi Hu; Zhao-Wu Tao; Jun-Hua Tian; Yuan-Yuan Pei; Ming-Li Yuan; Yu-Ling Zhang; Fa-Hui Dai; Yi Liu; Qi-Min Wang; Jiao-Jiao Zheng; Lin Xu; Edward C Holmes; Yong-Zhen Zhang
Journal:  Nature       Date:  2020-02-03       Impact factor: 49.962

6.  Questions concerning the proximal origin of SARS-CoV-2.

Authors:  Murat Seyran; Damiano Pizzol; Parise Adadi; Tarek M A El-Aziz; Sk Sarif Hassan; Antonio Soares; Ramesh Kandimalla; Kenneth Lundstrom; Murtaza Tambuwala; Alaa A A Aljabali; Amos Lal; Gajendra K Azad; Pabitra P Choudhury; Vladimir N Uversky; Samendra P Sherchan; Bruce D Uhal; Nima Rezaei; Adam M Brufsky
Journal:  J Med Virol       Date:  2020-09-03       Impact factor: 2.327

7.  SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects.

Authors:  Antoni G Wrobel; Donald J Benton; Pengqi Xu; Chloë Roustan; Stephen R Martin; Peter B Rosenthal; John J Skehel; Steven J Gamblin
Journal:  Nat Struct Mol Biol       Date:  2020-07-09       Impact factor: 15.369

8.  An update on the origin of SARS-CoV-2: Despite closest identity, bat (RaTG13) and pangolin derived coronaviruses varied in the critical binding site and O-linked glycan residues.

Authors:  Jeevan Malaiyan; Suresh Arumugam; Kamalraj Mohan; Gokul Gomathi Radhakrishnan
Journal:  J Med Virol       Date:  2020-07-14       Impact factor: 20.693

9.  Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak.

Authors:  Tao Zhang; Qunfu Wu; Zhigang Zhang
Journal:  Curr Biol       Date:  2020-03-19       Impact factor: 10.834

10.  The proximal origin of SARS-CoV-2.

Authors:  Kristian G Andersen; Andrew Rambaut; W Ian Lipkin; Edward C Holmes; Robert F Garry
Journal:  Nat Med       Date:  2020-04       Impact factor: 87.241

View more
  11 in total

Review 1.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

Review 2.  Janus kinase inhibitors for the treatment of COVID-19.

Authors:  Andre Kramer; Carolin Prinz; Falk Fichtner; Anna-Lena Fischer; Volker Thieme; Felicitas Grundeis; Manuel Spagl; Christian Seeber; Vanessa Piechotta; Maria-Inti Metzendorf; Martin Golinski; Onnen Moerer; Caspar Stephani; Agata Mikolajewska; Stefan Kluge; Miriam Stegemann; Sven Laudi; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2022-06-13

Review 3.  Biosensing surfaces and therapeutic biomaterials for the central nervous system in COVID-19.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  Emergent Mater       Date:  2021-03-10

Review 4.  Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.

Authors:  Annoor Awadasseid; Yanling Wu; Yoshimasa Tanaka; Wen Zhang
Journal:  Biomed Pharmacother       Date:  2021-01-28       Impact factor: 7.419

5.  Genomic Feature Analysis of Betacoronavirus Provides Insights Into SARS and COVID-19 Pandemics.

Authors:  Xin Li; Jia Chang; Shunmei Chen; Liangge Wang; Tung On Yau; Qiang Zhao; Zhangyong Hong; Jishou Ruan; Guangyou Duan; Shan Gao
Journal:  Front Microbiol       Date:  2021-03-17       Impact factor: 5.640

Review 6.  A systematic review of pregnant women with COVID-19 and their neonates.

Authors:  Mona Mirbeyk; Amene Saghazadeh; Nima Rezaei
Journal:  Arch Gynecol Obstet       Date:  2021-04-02       Impact factor: 2.493

7.  SARS-CoV-2's origin should be investigated worldwide for pandemic prevention.

Authors:  Zhiqiang Wu; Qi Jin; Guizhen Wu; Jian Lu; Mingkun Li; Deyin Guo; Ke Lan; Luzhao Feng; Zhaohui Qian; Lili Ren; Wenjie Tan; Wenbo Xu; Weizhong Yang; Jianwei Wang; Chen Wang
Journal:  Lancet       Date:  2021-09-17       Impact factor: 79.321

8.  Conserved molecular signatures in the spike protein provide evidence indicating the origin of SARS-CoV-2 and a Pangolin-CoV (MP789) by recombination(s) between specific lineages of Sarbecoviruses.

Authors:  Bijendra Khadka; Radhey S Gupta
Journal:  PeerJ       Date:  2021-11-12       Impact factor: 2.984

9.  Remdesivir for the treatment of COVID-19.

Authors:  Kelly Ansems; Felicitas Grundeis; Karolina Dahms; Agata Mikolajewska; Volker Thieme; Vanessa Piechotta; Maria-Inti Metzendorf; Miriam Stegemann; Carina Benstoem; Falk Fichtner
Journal:  Cochrane Database Syst Rev       Date:  2021-08-05

Review 10.  Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Zhi Xiong Chong; Winnie Pui Pui Liew; Hui Kian Ong; Chean Yeah Yong; Chong Seng Shit; Wan Yong Ho; Stephanie Y L Ng; Swee Keong Yeap
Journal:  Pathol Res Pract       Date:  2021-07-24       Impact factor: 3.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.